Chordate’s CEO presented at Swiss Nordic Bio
On March 7, Swiss Nordic Bio convened for its annual partnering and investor conference, facilitating connections between Nordic and Swiss life science companies, investors, and industrial partners. BioStock took the opportunity to ask a few questions to Anders Weilandt, CEO of Chordate Medical, who attended to present the medtech company.
Chordate Medical has developed Ozilia, a neuromodulation and drug-free treatment technology for the treatment of chronic migraine and chronic rhinitis. It is currently being introduced in selected markets in the EU and the Middle East.
Partnering and investor conference in Switzerland
The company’s CEO Anders Weilandt participated at the Swiss Nordic Bio 2024 in Zurich on March 7, where he presented the Ozilia treatment and the company’s marketing strategy. Formely known as Swiss Scandinavian Bio-Business Seminar, and with 17 years of tradition, the conference gathers a broad audience of startups and global companies in biotech, medtech and pharma, alongside other industry players and investors.
The CEO comments on the conference
Anders Weilandt attended the conference to increase awareness about Chordate Medical and Ozilia within the life science space, with a focus on investors and global stakeholders. The company has an exit strategy aimed at selling the company to a larger player, thereby expanding the marketing reach and growth for Ozilia. BioStock reached out to Anders Weilandt to learn more.
Why is it important for you to be at Swiss Nordic Bio and other similar conferences?
– This type of well-organized meetings serves as efficient platforms for companies like ours that aim to meet institutional investors and, most importantly, representatives of the global life science industry. We are now starting to build our network in this regard.
What did you focus on in your presentation of Chordate Medical and the Ozilia treatment?
– Primarily that we have a development project that has been de-risked in several steps. We are in the early commercial phase, entirely focused on our proven drug-free alternative for the preventive treatment of chronic migraines.
What type of players did you mostly engage with during the event?
– My focus was on scouts from global companies active in the migraine field, and on various types of investors.
What questions typically arise regarding the company and the Ozilia treatment, and how do you address these questions?
– It often revolves around how our medtech treatment compares to pharmaceuticals and how it is received by actual customers. We have a strong support from our latest study, PM007, which forms the basis of how we present our arguments.
Video interview
BioStock also managed to catch up with Anders Weilandt during the Swiss Nordic Bio event – watch the video interview below.
